Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vaidyane Ayurved Laboratories's annualized net income for the quarter that ended in Mar. 2026 was ₹83 Mil. Vaidyane Ayurved Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹648 Mil. Therefore, Vaidyane Ayurved Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 12.83%.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
NSE:MADHAVBAUG'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -7.75 Med: 10.05 Max: 15.71
Current: 15.1
During the past 8 years, Vaidyane Ayurved Laboratories's highest Return-on-Tangible-Equity was 15.71%. The lowest was -7.75%. And the median was 10.05%.
NSE:MADHAVBAUG's Return-on-Tangible-Equity is ranked better than 70.08% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:MADHAVBAUG: 15.10
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vaidyane Ayurved Laboratories Return-on-Tangible-Equity Related Terms
Vaidyane Ayurved Laboratories Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MADHAVBAUG vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.83% mean?
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Return-on-Tangible-Equity of 12.83% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 28% above median its historical median of 10.05. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #269 out of 899 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Vaidyane Ayurved Laboratories' Return-on-Tangible-Equity too high?
Vaidyane Ayurved Laboratories' current Return-on-Tangible-Equity of 12.83% is 28% above median its 10-year median of 10.05. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Vaidyane Ayurved Laboratories' value of 12.83% is 62.4% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #269 out of 899 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #269 out of 899 companies for Return-on-Tangible-Equity. This puts Vaidyane Ayurved Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Vaidyane Ayurved Laboratories' value of 12.83% is 62.4% above this benchmark. While the company's 10-year median is 10.05 vs. the industry median of 7.90, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Return-on-Tangible-Equity of 12.83% is 62.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Return-on-Tangible-Equity is 12.83%, which is 28% above median its own 10-year median of 10.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Fairly Valued. The stock's GF Value™ is ₹228.15, compared to a current price of ₹208.80 — trading 8.5% below its estimated fair value. The current Return-on-Tangible-Equity is 12.83%, which is 28% above median its 10-year median of 10.05 and 62.4% above the Drug Manufacturers industry median of 7.90. Vaidyane Ayurved Laboratories' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Return-on-Tangible-Equity is 12.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹208.80 is trading 8.5% below its estimated GF Value™ of ₹228.15.
GuruFocus considers Vaidyane Ayurved Laboratories to be Fairly Valued.
Key valuation signals for NSE:MADHAVBAUG:
Return-on-Tangible-Equity: 12.83% (28% above median its 10-year median of 10.05)
GF Value™: ₹228.15 vs. price of ₹208.80 (8.5% below fair value)
Industry Position: 62.4% above the Drug Manufacturers median (#269 of 899)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
78GF Score
Get the complete analysis for NSE:MADHAVBAUG
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
